Edward Inns

Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals.

BII Group Ltd. (BII Group) is a private equity/venture capital, a subsidiary of Government of United Kingdom was founded by James Murray Grant in 1948. The firm is headquartered in London with offices in Bengaluru, Mumbai, Nairobi, Pakistan, Sandton, and Bangladesh.

Cinven Group Ltd (Cinven Group) is a private equity firm founded in 1977. The firm is headquartered in London, United Kingdom.

BC Partners Ltd. (BC Partners) is an Independent Private Equity firm founded in 1986. BC Partners Ltd. is headquartered in London with additional offices in Hamburg, Paris and New York.

ECI Partners LLP (ECI Partners) is a private equity founded in 1976. The firm is headquartered in London, the United Kingdom with an additional offices in Manchester and New York.

Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom.

The Royal Society of Medicine provides postgraduate medical education. The Society provides a range of educational activities and opportunities for doctors, dentists and veterinary surgeons, including students, and for allied healthcare professionals. It also promotes an exchange of information and ideas on the science, practice and organization of medicine, both within the health professions and with responsible and informed public opinion. The Society was founded in 1805 and is headquartered in London, the United Kingdom.

Part of Eli Lilly & Co., Lilly Research Laboratories is a company that engages in research and develops medicines. The company is based in Indianapolis, IN.

Bain Capital LLC is one of the world's leading private investment firms managing approximately $66 billion in assets under management. Their affiliated advisors make private equity, public equity, leveraged debt asset, venture capital, and absolute return investments across multiple sectors, industries, and asset classes. Since their inception, their competitive advantage has been grounded in a people-intensive, value-added investment approach that has enabled the firm to deliver industry-leading returns for their investors.

Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge.

Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom.

Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU.

Part of Merck & Co., Inc., Organon Laboratories Ltd. is a company based in Hoddesdon, UK.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.

Easybill SAS provides online customer relationship management and invoice software solutions. It focuses around ERP functionality, such as invoicing. Easybill's features include CRM, teamwork, timetracking, purchases, stocks, help desk, and point of sale. The company was founded by Frédéric Coulais and Alain Mevellec in 2009 and is headquartered in La Rochelle, France.

Abcodia Ltd. engages in the validation and discovery of molecular biomarkers. The firm works alongside University College London and in partnership with diagnostic, pharmaceutical and technology companies to exploit a prospective serum bank for the purpose of ethical biomarker validation and discovery. The company was founded in 2010 and is headquartered in London, the United Kingdom.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.

Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom.

Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom.

CMR Surgical Ltd. develops universal robotic system for minimal access surgery. The firm is presently evaluating the ability of the versius system to perform upper GI, gynaecological, colorectal and renal surgery in cadaveric trials. The company was founded by Martin Frost and Mark Slack in January 2014 and is headquartered in Cambridge, the United Kingdom.

The World Bank (Research) (World Bank-Research) is the investment research division of The World Bank, an international financial institution headquartered in Washington, DC. It provides loans and grants to the governments of low- and middle-income countries for the purpose of pursuing capital projects. World Bank-Research provides research to developing nations to aid economic advancement.

Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom.

Sense Biodetection Ltd. provides molecular diagnostics research services. It focuses on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology. The company was founded by Harry John Lamble and Ralph Lamble in 2014 and is headquartered in Abingdon, the United Kingdom.

Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom.

Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom.

MapLight Therapeutics, Inc. engages in the development of novel therapeutics for brain disorders. The company is headquartered in San Francisco, CA.

Ophirex, Inc. develops antidotes to snakebite. The company was founded by Jerry D. Harrison and Matthew Lewin and is headquartered in Corte Madera, CA.

Start Codon Ltd (Start Codon) is a venture capital firm founded in 2018 by Jason Mellad and Marek Tyl. The firm is headquartered in London, United Kingdom.

Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom.

Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom.